Gianluca Bartoli

cis-Pt I2(NH3)2: a reappraisal.

V. Brabec, J. Kašpárková, A. Arcangeli, 2015, Dalton transactions.

Novel strategies to overcome Cisplatin resistance in colorectal cancer.

G. Bartoli, Gianluca Bartoli, 2016 .

New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules

R. Hoogenboom, L. Massai, L. Messori, 2018, BioMetals.

Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles

L. Massai, L. Messori, M. Cinellu, 2016, BioMetals.

The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

K. Chandy, O. Crociani, A. Becchetti, 2017, British Journal of Cancer.

The combined activation of K Ca 3.1 and inhibition of K v 11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

Roberto, K. Chandy, O. Crociani, 2017 .

hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy

F. di Costanzo, L. Messerini, L. Antonuzzo, 2016, OncoTargets and therapy.